Cosmos Health Launches Oliv18 Supplement, Expanding into $33B Cardiovascular and Antioxidant Markets
COSM is trading near its 52-week low of $0.245 (12% above the low) on elevated volume (2.1× avg).
Summary
Cosmos Health announced the U.S. launch of Oliv18, a new nutraceutical supplement targeting the cardiovascular and antioxidant categories. This expands the company's "18 Series" platform, following previous product announcements like NOOR collagen and Liv18 liver health supplement. While the product targets a combined global market projected to exceed $33 billion by 2035, the immediate financial impact of this specific launch is not quantified. This development occurs as the company faces significant financial challenges, including a going concern warning, widened losses, and increased cash burn reported in its Q1 2026 10-Q.
At the time of this announcement, COSM was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $0.25 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.